Sunday, July 02, 2006

Tesmilifene Gets Fast-Track Status for Breast Cancer

YM Biosciences, Inc. has recently been granted fast-track status for its lead drug Tesmilifene (DDPE). The indication is for the treatment of advanced breast cancer to be used in combination with an anthracycline-based regimen. Tesmilifene is considered to be a small molecule chemopotentiator that is currently being evaluated in a phase III clinical trial. The trial includes 700 patients with advanced or recurrent breast cancer comparing epiribucin and cyclophosphamide with or without tesmilifene. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */